Please upgrade your browser.
According to a study, a blood test could predict kidney cancer risk and survival, five years prior to its diagnosis.
Researchers from Wellcome Sanger Institute, the University of Cambridge and the University of Newcastle discovered that adult renal carcinoma cells are a version of a specific rare subtype of healthy adult kidney cell, called PT1. They found that despite genetic differences, all the renal carcinoma cells studied had developed the same PT1 characteristics. These results could provide the basis of a new method for treating cancer by targeting the PT1 cell specifically.
Kidneys are one of the most important organs in our body. Kidneys helps with the metabolism of the body, regulated blood volume and pressure, makes red blood cells, keeps the bones strong and gets rid of the all the waste accumulated in our bodies. Our unhealthy lifestyle and strenuous lives put the kidneys under stress and they become susceptible to kidney stones, infections, cysts, tumor, and a kidney failure.
Asheville firefighter Will Willis died of kidney cancer earlier this year. The Asheville Citizen-Times first reported that for just the second time in such cases, the North Carolina Industrial Commission decided it was a line-of-duty death.
Hypermethylation has been documented in some myeloid disorders including myelodysplastic syndrome (MDS) and in renal cell carcinoma (RCC). A group at the Mayo Clinic noticed the epigenetic marking patterns between these vastly different conditions and wondered if there was a connection. The group found that there was a strong association.
Researchers have identified relapse patterns of nonclear cell renal cell carcinomas — an understudied group of rare kidney cancers — that are distinct from the more common clear cell renal cell carcinomas. The findings may help improve the management of patients with nonclear cell renal cell carcinomas (non-ccRCC), who represent approximately 20 percent of kidney cancer patient populations.
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).
This video discusses strategies for metastatic renal cell carcinoma that involve I-O therapies in combination with VEGF-targeted therapies.
Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Méjean et al found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.
|Powered by NeonCRM|